You are here
Program News and Releases
Patient Cells Yield Potential Therapies For Familial Dysautonomia
Lorenz Studer reports the first large-scale drug discovery screen based on an iPSC-derived disease model.
Two NYSTEM-funded Scientists Elected as Fellows to AAAS
Drs. Shahin Rafii and Ming-Ming Zhou were elected as Fellows of the American Association for the Advancement of Science.
The Ubiquitin-Proteasome System Adds Complexity to Pluripotency and Reprogramming
New data from Iannis Aifantis shows the Ubiquitin-Proteasome System functions in both reprogramming and differentiation of pluripotent stem cells, partially through targeting of c-Myc.
Amniotic Fluid Cells Reprogrammed to Endothelial Cells
Shahin Rafii reports the efficient direct conversion of amniotic fluid-derived cells into functional vascular endothelial cells.
Gene Therapy for α-Thalassemia in iPS Cells
Dr. Eric Bouhassira reports zinc finger nuclease-mediated gene correction for α-thalassemia in patient iPSCs.
Molecular Mechanisms of Reprogramming Unveiled
New research from Dr. Asa Abeliovich provides insight to the molecular mechanisms of reprogramming.
Identification of a Key Regulatory Factor in Hematopoiesis and Cancer
New data from Dr. Ulrich Steidl identifies a key transcription factor that regulates hematopoiesis and promotes acute myeloid leukemia.
Novel Gene Sets Identified that Regulate the Survival of Leukemia Stem Cells
Leukemia stem cells (LSCs) represent a biologically distinct subpopulation of myeloid leukemias, with reduced cell cycle activity and increased resistance to therapeutic challenge.
A New Method to Improve the Yield of RBCs Over 100-fold
Eric Bouhassira’s group defines a method to improve the yield of RBCs over 100-fold. RBCs are critical for blood transfusions in surgeries, trauma care, and blood diseases such as sickle cell disease. Dr. Bouhassira and colleagues at the Albert Einstein College of Medicine combined several different methodologies to increase the number of RBCs in a sample by over 100-fold, and can envisage significant further improvements.
FDA Approves Trial of Stem Cell-Based Gene Therapy for Blood Disease
Dr. Michel Sadelain leads a team developing a potential cure for β-thalassemia.